|1.02||+0.0336||+3.41%||Vol 5.82M||1Y Perf -93.80%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||-0.02 -1.96%|
|Target Price||32.50||Analyst Rating||Moderate Buy 2.00|
|Potential %||3.09K||Finscreener Ranking||★★★★ 53.33|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 57.62|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 56.09|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||2.39||Earnings Rating||Strong Buy|
|Market Cap||72.25M||Earnings Date||14th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.48|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||3.38M|
|Avg. Monthly Volume||8.94M|
|Avg. Quarterly Volume||3.53M|
Aclaris Therapeutics Inc. (NASDAQ: ACRS) stock closed at 0.9864 per share at the end of the most recent trading day (a 0.39% change compared to the prior day closing price) with a volume of 1.92M shares and market capitalization of 72.25M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 60 people. Aclaris Therapeutics Inc. CEO is Neal Walker.
The one-year performance of Aclaris Therapeutics Inc. stock is -93.8%, while year-to-date (YTD) performance is -93.74%. ACRS stock has a five-year performance of -88.52%. Its 52-week range is between 0.5902 and 18.54, which gives ACRS stock a 52-week price range ratio of 2.39%
Aclaris Therapeutics Inc. currently has a PE ratio of -12.80, a price-to-book (PB) ratio of 5.02, a price-to-sale (PS) ratio of 49.44, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -33.44%, a ROC of -37.49% and a ROE of -40.70%. The company’s profit margin is -%, its EBITDA margin is -353.50%, and its revenue ttm is $22.00 Million , which makes it $0.33 revenue per share.
Of the last four earnings reports from Aclaris Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.48 for the next earnings report. Aclaris Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aclaris Therapeutics Inc. is Moderate Buy (2), with a target price of $32.5, which is +3 086.27% compared to the current price. The earnings rating for Aclaris Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aclaris Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aclaris Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 30.36, ATR14 : 0.30, CCI20 : -39.12, Chaikin Money Flow : 0.05, MACD : -1.06, Money Flow Index : 74.92, ROC : 11.43, RSI : 21.84, STOCH (14,3) : 83.07, STOCH RSI : 1.00, UO : 56.04, Williams %R : -16.93), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aclaris Therapeutics Inc. in the last 12-months were: Anand Mehra (Option Excercise at a value of $0), Balthaser Kevin (Buy at a value of $74 971), Balthaser Kevin (Sold 0 shares of value $0 ), Douglas J. Manion (Buy at a value of $50 278), Douglas J. Manion (Sold 0 shares of value $0 ), Gowen Maxine (Option Excercise at a value of $0), Humphries William (Option Excercise at a value of $0), James Loerop (Buy at a value of $99 994), James Loerop (Sold 0 shares of value $0 ), James Loerop (Sold 4 267 shares of value $59 272 ), Joseph Monahan (Sold 5 000 shares of value $65 311 ), Milano Vincent (Option Excercise at a value of $0), Molineaux Christopher (Option Excercise at a value of $23 603), Monahan Joseph (Option Excercise at a value of $0), Monahan Joseph (Sold 41 837 shares of value $512 603 ), Neal Walker (Sold 70 000 shares of value $1 104 479 ), Powell Andrew (Option Excercise at a value of $0), Reasons Bryan (Option Excercise at a value of $0), Schiff Andrew (Option Excercise at a value of $0), Walker Neal (Option Excercise at a value of $0), Walker Neal (Sold 129 240 shares of value $1 845 322 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.